External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>The company’s US revenue stood at $226 Mn, reflecting a 9.6% YoY decline impacted by gRevlimid and a 2.3% increase QoQ on improved lanreotide sales.</li><li>One India’s segment grew 6% YoY, driven by muted therapies such as Respiratory. Chronic products. These now contribute 61.5% of revenue, continuing to outperform IPM growth, while the Acute segment remains affected by seasonal headwinds.</li><li>The South Africa business expanded 30% YoY, aided by robust growth in the private market and OTC market.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The company’s US revenue stood at $226 Mn, reflecting a 9.6% YoY decline impacted by gRevlimid and a 2.3% increase QoQ on improved lanreotide sales.One India’s segment grew 6% YoY, driven by muted therapies such as Respiratory. Chronic products. These now contribute 61.5% of revenue, continuing to outperform IPM growth, while the Acute segment remains affected by seasonal headwinds.The South Africa business expanded 30% YoY, aided by robust growth in the private market and OTC market.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cipla Ltd - Promising Pipeline, Maintain BUY

<ul><li>The company’s US revenue stood at $226 Mn, reflecting a 1.7% YoY decrease, although this was affected by lower Lanreotide supply issues. </li><li>India’s branded prescription segment grew by 10% YoY as key therapies like Respirator, Urology, etc.has performed well.</li><li>Chronic products now comprise 61.5% of revenue, continuing to outpace IPM growth. However, the Acute segment remains impacted by seasonal challenges.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The company’s US revenue stood at $226 Mn, reflecting a 1.7% YoY decrease, although this was affected by lower Lanreotide supply issues. India’s branded prescription segment grew by 10% YoY as key therapies like Respirator, Urology, etc.has performed well.Chronic products now comprise 61.5% of revenue, continuing to outpace IPM growth. However, the Acute segment remains impacted by seasonal challenges.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CIPLA Ltd - CIPLA Delivers Despite U.S. Struggles

External broker reports(aggregated public sources), Sharekhan

Sharekhan

Sharekhan is India's leading broking house providing services from easy online trading, research to wide array of financial products. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Sharekhan's research report onCipla Cipla’s revenue reached Rs. 7,051 crore, reflecting a 7% y-o-y increase and a 6% q-o-q rise, meeting our expectations.</li><li>EBITDA stood at Rs. 1,886 crore with 15% y-o-y growth; it slightly missed our estimates by 1% and margins remained steady at 27%.</li><li>Cipla is poised for growth in North America, driven by demand for its generic asthma drug and cancer injectables, along with four new approvals secured during the quarter.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sharekhan's research report onCipla Cipla’s revenue reached Rs. 7,051 crore, reflecting a 7% y-o-y increase and a 6% q-o-q rise, meeting our expectations.EBITDA stood at Rs. 1,886 crore with 15% y-o-y growth; it slightly missed our estimates by 1% and margins remained steady at 27%.Cipla is poised for growth in North America, driven by demand for its generic asthma drug and cancer injectables, along with four new approvals secured during the quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cipla Ltd - Meaningful New Launches to Drive Growth

<ul><li>The company’s US revenue stood at $237 Mn, reflecting a 3.5% YoY increase, although this was affected by lower Lanreotide sales as the partner’s manufacturing plant underwent capacity expansion.</li><li>India’s branded prescription segment grew by 4.7%, with seasonal impacts on the acute category, which increased by 4.9% compared to 12% in the previous quarter.</li><li>Chronic products now comprise 61% of revenue, continuing to outpace IPM growth.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The company’s US revenue stood at $237 Mn, reflecting a 3.5% YoY increase, although this was affected by lower Lanreotide sales as the partner’s manufacturing plant underwent capacity expansion.India’s branded prescription segment grew by 4.7%, with seasonal impacts on the acute category, which increased by 4.9% compared to 12% in the previous quarter.Chronic products now comprise 61% of revenue, continuing to outpace IPM growth.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CIPLA Ltd - Regulatory Hurdles Cloud the Outlook

External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Cipla delivered in-line 1QFY25 performance.</li><li>It continued to track well in the US generics segment, with sales scaling an all-time quarterly high of USD250m.</li><li>However, the benefit was partly offset by a temporary disruption in the trade generics segment.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cipla delivered in-line 1QFY25 performance.It continued to track well in the US generics segment, with sales scaling an all-time quarterly high of USD250m.However, the benefit was partly offset by a temporary disruption in the trade generics segment.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cipla - The US and Emerging Markets Drive Earnings

India

Cipla Limited manufactures and sells pharmaceutical and personal care products. The Company offers active pharmaceutical ingredients, and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, steroids, iron chelators, nutritional products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cipla Ltd (CIPLA IN)

Cipla Ltd - Promising Pipeline, Maintain BUY

The company’s US revenue stood at $226 Mn, reflecting a 9.6% YoY decline impacted by gRevlimid and a 2.3% increase QoQ on improved lanreotide sales.

Axis Direct

CIPLA Ltd - CIPLA Delivers Despite U.S. Struggles

The company’s US revenue stood at $226 Mn, reflecting a 1.7% YoY decrease, although this was affected by lower Lanreotide supply issues.

Axis Direct

Cipla Ltd - Meaningful New Launches to Drive Growth

Sharekhan's research report onCipla Cipla’s revenue reached Rs. 7,051 crore, reflecting a 7% y-o-y increase and a 6% q-o-q rise, meeting our...

Sharekhan

CIPLA Ltd - Regulatory Hurdles Cloud the Outlook

The company’s US revenue stood at $237 Mn, reflecting a 3.5% YoY increase, although this was affected by lower Lanreotide sales

Axis Direct

Cipla - The US and Emerging Markets Drive Earnings

Cipla delivered in-line 1QFY25 performance. It continued to track well in the US generics segment, with sales scaling an all-time quarterly high of...

Motilal Oswal

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)